IMS Health Germany Could you give us a brief introduction to IMS’ business model? What would you say are the main challenges encountered today in the German market for IMS? IMS has been the partner of the pharmaceutical industry for over fifty years and has evolved alongside it. IMS today is the partner…
Argentine Ministry of Science ¿Porque fue creado en Ministerio de Ciencia y Tecnología, con que visión? Muchos países están aportando importancia a la ciencia y tecnología y representa la razón del desarrollo económico y social de esos mismos países. El ministerio en Argentina se creó en ese sentido, para ayudar a transformar el conocimiento…
Baxter Germany Next year Baxter will accomplish its 50th anniversary in Germany. In the context of its celebration, what would you highlight as the main achievements of the company especially since you took the reigns of the German operations? Baxter Germany has grown steadily in the German market primarily thanks to its…
DKFZ - German Cancer Research Center The DKFZ – German Cancer Research Center – is Germany’s largest cancer research institute with an international recognition recently coroneted with the Nobel Prize to Mr Harald zur Hausen for the HPV vaccine. What were the set of values and visions that allowed the DKEZ to have such a prominent…
Ministry of Health Indonesia Overall health indicators have improved significantly in Indonesia in recent years. However, the country still faces many challenges and there are many areas in need of further improvement. What is your assessment on how government policy is contributing toward improved health care in terms of current policies and priorities? Indonesia’s…
Medy-Tox What drove you to make the move from the academia to the business sector when you decided to establish Medy-Tox in 2000? I founded Medy-tox in the year 2000, in the context of a very difficult economic moment for Korea which was facing strong financial restrictions on government spending imposed…
Ministry of Health & Welfare Italy Following the successful result of the “Piano Sanitario Nazionale” 2005 – 2008, could you introduce to ours readers the key priorities and main health policies to be implemented by 2009 onwards to foster maximum quality and equality in health for all citizens, highlighting those concerning preventive Health? The current government…
Minister for Health How would you rate South Korea’s healthcare system when compared to regional peers and other OECD countries – main strong points and room for improvement? Since the introduction of the national health insurance system in 1977, the Korean national healthcare system has been experiencing dramatic growth, guaranteeing healthcare to every…
Gilead Sciences Germany Gilead was founded in 1987 and only four years later it established itself in the German market. Since then the company has become internationally known for breakthroughs that resulted in products such as Tamiflu, Viread and Atripla. What would you highlight as the main achievements of the company in the…
TEVA Germany The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process continued with the recent acquisition of AWD Pharma in 2008. What as the impact of such acquisitions in your German…
Boehringer Ingelheim Indonesia After 20 years experience with Boehringer Ingelheim, what would you say are the main specificities of the Indonesian pharmaceutical industry? Indonesia differs some what from other Asian countries, starting from being a non reimbursement market with a very large population, to people having a small disposable income. Indonesia also has…
Astellas Pharma Germany Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the two companies. Could you describe their integration process in Germany and which were the main synergies in the local market?…
See our Cookie Privacy Policy Here